GT Biopharma
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1965-01-01
- Employees
- 2
- Market Cap
- -
- Website
- http://www.gtbiopharma.com
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
Phase 1
Terminated
- Conditions
- Mast Cell LeukemiaAcute Myelogenous LeukemiaHigh-risk Myelodysplastic SyndromesSystemic Mastocytosis
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- GT Biopharma, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03214666
- Locations
- 🇺🇸
University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States
🇺🇸Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath